SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent
ACRS 2.425+3.6%2:46 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: BioHero9/25/2019 8:54:09 AM
   of 23
 
Eskata approval in Canada expected within 3 Weeks will trigger milestone payment to ACRS and will push stock much higher again .And there is more tocomeduring the Q4like licensing deals and the readout of the second Phase 3 trial .Market Cap $51.5 Million /Cash balance $115 Million

Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada...Dec. 18, 2018
cipher.investorroom.com

A-101 40% is a U.S. Food and Drug Administration ("FDA")-approved product indicated for the treatment of raised SKs, which are commonly occurring non-cancerous skin growths that affect more than 9 million Canadian adults and can be an aesthetic skin concern.

About Seborrheic Keratoses
SKs are non-cancerous skin growths that affect an estimated 20% of the population and are most commonly seen in middle-aged and older adults. SKs vary in color from flesh-colored to pink, yellow, gray, tan, brown, or black; can range in size from a millimetre to a few centimetres wide; and typically have a slightly elevated, waxy or scaly appearance. The number and size of SKs tends to increase with advancing age. SKs frequently appear in highly visible locations, such as the face or neck, but can also appear anywhere on the body, except the palms, soles and mucous membranes.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext